Celltrion is a South Korean biopharmaceutical company established in 2002 that develops, manufactures, and markets biosimilar drugs (highly similar versions of biologic drugs) with the goal of making advanced therapeutics more affordable and accessible to patients worldwide. Their first biosimilar drugs Remsima (infliximab) and Herzuma (trastuzumab) have been approved in multiple countries. Celltrion has extensive R&D, manufacturing, and clinical trial experience that has enabled the successful development and approval of their biosimilar monoclonal antibody drugs. They have a robust pipeline of additional biosimilar candidates in development.

1. Advanced Therapeutics Within Everyone’s Reach
www.celltrion.com

2. Advanced Therapeutics Within
Everyone’s Reach.
Our History
Since our foundation in 2002, we have concentrated our
investments in human resources, facilities and technologies with
the singular goal of becoming a global biopharmaceutical company
that develops, manufactures and markets affordable advanced
therapeutics based on recombinant DNA and molecular biology.
As of 2015, we have obtained marketing authorizations for
Remsima® and HerzumaTM
, our two biosimilar monoclonal
antibodies (mAbs). Remsima®, the world’s first biosimilar mAb, has
already been approved not only in Korea but also in many countries
around the world, including those in Europe and the US. HerzumaTM
,
the world’s first anti neoplastic biosimilar mAb, has thus far been
approved in Korea. Application for its approval is planned to be
submitted in other countries.
Our bid to become a world-class biopharmaceutical company
continues today with our eyes set firmly on serving the needs of
patients through development of affordable biosimilar mAbs and
innovative next-generation drugs.
To promote patient access to advanced
therapeutics, we have been committed
to bringing affordable drugs to patients
who previously had limited access to
them.
Every patient should have access to
advanced therapeutics they need.
At Celltrion, we believe that patients
deserve the very best treatment
without cost considerations being a
limiting factor.
Feb. 2002 Celltrion is founded
Jun. 2005 Supply Agreement with a US pharmaceutical company
Jul. 2005 Mechanical completion of Plant 1 (capacity: 50,000L)
Dec. 2007 Plant 1 receives cGMP facility approval by the US FDA
Aug. 2009 IND approval of HerzumaTM (for breast cancer treatment)
Oct. 2009 Completion of global sales network
Mar. 2010 IND approval of Remsima®
(for rheumatoid arthritis, ankylosing spondylitis treatment)
May. 2010 Strategic direct investment by Temasek
Dec. 2010 Mechanical completion of Plant 2 (capacity: 90,000L)
Dec. 2011 IND approval of biosimilar candidate CT-P10
(for rheumatoid arthritis and Non Hodgkin’s lymphoma)
Jul. 2012 Remsima® approved by Korea Ministry of Food and
Drug Safety (MFDS, formerly, KFDA)
Apr. 2013 IND approval of CT-P27 (for universal influenza treatment)
Aug. 2013 Remsima® approved by the EMA
Nov. 2013 Completion of global clinical trial phase 1 for CT-P27
Jan. 2014 HerzumaTM approved by the MFDS
Remsima® approved by Health Canada
Jul. 2014 Remsima® approved by MHLW (Japan), MoH (Turkey)
Aug. 2014 Completion of global clinic trial phase 2a for CT-P27
Feb. 2015 Remsima® launched in Europe (12 countries including
Germany, France, England, Italy, Spain)
Apr. 2015 Remsima® approved by ANVISA (Brazil), INHRR (Venezuela)
Oct. 2015 TruximaTM (CT-P10) filed for EMA approval
Dec. 2015 TruximaTM (CT-P10) filed for MFDS approval
Apr. 2016 Remsima® approved by the US FDA
Celltrion

3. Monoclonal antibodies-paving
a new way for biosimilars
Biologics, especially mAbs, are revolutionary therapeutics, considered to
be one of the fastest growing sectors of the pharmaceutical industry.
Biologics have introduced many novel therapeutics to life-threatening and
rare diseases since the late 1980’s.
Although mAbs have treated many patients through their unique mode
of action that targets specific antigens, these highly effective drugs have
been beyond the reach of far more patients due to their extremely high
price. Annual costs of biologics treatment can be as much as 20 times
greater than treatments using chemical drugs.
It is estimated that about USD 66 billion of branded biologic sales will
lose patent protection over the next few years, including some of the
bestselling ones.
With this opportune timing, many global pharmaceutical companies are
on the rush to develop biosimilar mAbs, with Celltrion at the head of the
competition.
The market landscape of biosimilars
• Patent expiry in many of the world’s largest biopharmaceuticals in the
coming years is allowing for biosimilar expansion.
• Rising healthcare expenditure outpacing economic growth is boosting
demand for more affordable drugs.
What do biosimilars mean for the healthcare industry?
• For healthcare providers: an opportunity to provide affordable care
• For patients: access to affordable advanced therapeutics
• For Celltrion: reaching its vision of promoting patient access to
advanced therapeutics at affordable price
Biosimilars, a new horizon in
global pharmaceutical industry
A new era of biosimilars has begun.
Biosimilars are officially approved
subsequent versions of innovator biologics
that may provide opportunities for
reducing the cost of treatment without
compromising quality.
Approximately 40 percent of biosimilars
currently in development are monoclonal
antibodies (mAbs).
That percentage is likely to only grow with
the rising demand for biosimilar versions
of the originator mAbs to offset prohibitive
costs of the originator mAbs.
BiosimilarIndustry

4. Stepwise business development to maximize success
and minimize risk
Since 2002, we have built world-class facilities, developed state-of-
the-art technologies and put quality systems in place.
We also secured the cash flow necessary for developing our own
products through our CMO business.
Using the technology and know-how in biologics development
we have thus accumulated over the years, we soon succeeded in
developing biosimilar mAbs and establishing global marketing and
sales network through strategical partnerships with a number of
major global pharmaceutical distributors.
Strong Capability of Research & Development
R&D is at the center of Celltrion’s mission as Celltrion strives to
transform innovative research into advanced therapeutics.
Over 250 well-experienced researchers (75% MS & 25% Ph.D) are
dedicated to the strong biosimilar pipeline and new product pipeline
including new monoclonal antibodies and vaccines that target
infectious diseases at Celltrion R&D Center.
Core research activities range from target screening to non-clinical
design. The capabilities of Celltrion R&D combined with well-
established infrastructures have led to successful drug development.
State-of-the-art manufacturing facilities
Celltrion boasts one of the world's largest state-of-the-art
mammalian cell culture plants with a total production capacity of
140,000L.
These plants were designed and constructed to comply with the US
FDA’s cGMP and the EMA’s GMP regulations.
Excellence in clinical study design and
global biosimilar mAb approval experience
From the very earliest stages of our biosimilar mAb development,
we have thoroughly reviewed regulatory requirements for each
individual country to design global clinical trials that would
encompass even the most stringent regulatory requirements.
Thanks in no small part to such unrelenting efforts, Celltrion
accomplished the historical feat of successfully obtaining approval
from the EMA, US FDA and the MFDS for Remsima®, the world’s
very first approved biosimilar mAb.
Key factors behind Celltrion’s successful
biosimilar mAb development
Celltrion was already
strategically preparing for
biosimilar mAb development
well before other global
biopharmaceutical companies
even realized the biosimilar
market potential.
Biosimilar Candidate Target(INN) Original Product Major Indication
CT-P17 Adalimumab Humira Rheumatoid arthritis
CT-P16 Bevacizumab Avastin Colon cancer
CT-P15 Cetuximab Erbitux Colorectal cancer
CT-P14 Palivizumab Synagis RSV Infant
CT-P05 Etanercept Enbrel Rheumatoid arthritis
BiosimilarDevelopment
Affordable solutions
for advanced therapeutics
Our biosimilar mAb
products & pipeline
In addition to HerzumaTM and Remsima®,
we have a robust pipeline consisting of as many as six biosimilar
mAb candidates. From this pipeline, we plan to launch products
on an annual basis. Following on the heels of Remsima® and
HerzumaTM, the development of CT-P10, our third biosimilar mAb, is
progressing on schedule with successful clinical trial phase 1 results.
CT-P10 is currently in global clinical trial phase 3. In 2015, Celltrion
submitted a Market Authorization Application (MAA) for CT-P10 to
the EMA.
Product Target(INN) Original Product Major Indication Current Status
Remsima®
Infliximab Remicade Rheumatoid arthritis
∙ MFDS approval 2012
∙ EMA approval 2013
∙ Health Canada, MHLW(Japan) and
TITCK(Turkey) approval 2014
∙ ANVISA(Brazil), INHRR(Venezuela)
approval 2015
∙ US FDA approval 2016
HerzumaTM
Trastuzumab Herceptin Breast cancer ∙ MFDS approval 2014
TruximaTM
Rituximab Rituxan Non-Hodgkin lymphoma ∙ Filed for EMA, MFDS approval
Biosimilar mAb products
Biosimilar mAb pipeline

5. 1) : “Indications approved vary among countries. This is a collective list of indications
approved by countries in which CT-P13 is approved. Country-specific information
is available upon request at gmkt@celltrion.com
Remsima®
global clinical
trial overview
Clinical trial period
March 2010 - November 2012
Number of patients
Total 874 | Phase 1: 250, Phase 3: 606
Number of countries and sites
Phase 1: 10 countries 46 sites
Phase 3: 19 countries 100 sites
• INN: Trastuzumab
• Approval status: Approved by the MFDS
• Indications: Metastatic breast cancer, early stage breast cancer and
metastatic gastric cancer with over-expression of human epidermal
growth factor receptor 2 protein (HER2)
• Protein type: Monoclonal antibody (mAb)
• Mechanism of action: The antibody specifically binds to the antigen
and suppresses the antigen signals to target and destroy tumor.
• Trastuzumab market size: Approximately USD 7 billion (as of 2015)
HerzumaTM
is our trastuzumab
biosimilar which had been
demonstrated comparable with the
originator trastuzumab for breast
cancer treatment by multinational
randomized double blind clinical
trials.
HerzumaTM
global clinical
trial overview
Clinical trial period (MBC)
August 2009 - June 2012
Number of patients
Total 557 | Phase 1: 174, Phase 3: 383
Number of countries and sites
Phase 1: 7 countries 31 sites
Phase 3: 22 countries 99 sites
Remsima®
is an alternative to the
originator infliximab in approved
countries. In more than seventy
countries Remsima®
is approved
and used for treatment of
rheumatoid arthritis and certain
other autoimmune diseases.
Remsima®&HerzumaTM
the world’s first
approved
biosimilar mAb
the only oncology
biosimilar mAb
approved based on
global clinical trial
results
• INN: Infliximab
• Approval status: Approved by the EMA, US FDA, Health Canada,
MHLW (Japan), ANVISA (Brazil) and the MFDS (Korea), etc.
• Indications1) : Rheumatoid arthritis, ankylosing spondylitis,
ulcerative colitis, Crohn's disease, psoriasis and psoriatic arthritis
• Protein type: Monoclonal antibody (mAb)
• Mechanism of action: Neutralizes tumor necrosis factor (TNF-alpha),
a common cause of autoimmune diseases such as rheumatoid arthritis
• TNF antagonist market size: Approximately USD 32.9 billion
(as of 2015)
*Under Phase 3 for EBC protocols

6. Universal influenza antibody CT-P27
Most notably, in August 2014, Celltrion completed phase 2a
clinical trial for CT-P27, a novel therapeutic antibody under
development for treatment against various types of influenza
viruses.
CT-P27, a cocktail injectable made up of two different monoclonal
antibodies developed by Celltrion, has been drawing keen
interests from the US and Chinese governments for targeting
neutralization of a broad spectrum of influenza viruses including
seasonal strains and potential pandemic strains. Through its mode
of action which is distinct from existing influenza treatments,
CT-P27 aims to neutralize even those influenza viruses that have
become resistant to currently existing neuraminidase inhibitors.
Celltrion projects that its non-clinical and clinical studies have the
potential to demonstrate CT-P27 as possible treatment of various
types of influenza virus infection.
Beyond
biosimilar mAbs
Our novel
Therapeutics
Beyond biosimilar mAbs,
Celltrion is also developing its own
novel biopharmaceuticals using the
R&D capabilities and technologies
it has accumulated over the years
through its biosimilar development.
Project Target Indication
CT-P27 (mAb) Influenza virus infections
CT-P26 (ADC) Breast cancer
CT-P25 (cell-based vaccine) Influenza
CT-P24 (mAb) Hepatitis B virus
CT-P19 (mAb) Rabies
In addition to CT-P26, Celltrion is developing an antibody-drug conjugate (ADC) for breast cancer. ADC’s are mAbs chemically linked
to cytotoxic drug so as to minimize side effects and maximize efficacy.
We are also developing an antiviral medication for pandemic and seasonal influenza which we hope will overcome the limitations of
existing vaccines and synthetic drugs.
NovelTherapeutics
Novel therapeutics pipeline
Innovation at work
Our novel therapeutics pipeline

7. Contact Information
Celltrion, Inc. 23, Academy-ro, Yeonsu-gu, 406-840, Incheon, South Korea T. +82-32-850-5000 F. +82-32-850-5078 Webpage. www.celltrion.com
E-MAIL・Business : contact@celltrion.com・Investment : investor@celltrion.com・Legal : legal@celltrion.com・Careers : recruit@celltrion.com
@2016.05Celltrion